The potential benefits of low-molecular-weight heparins in cancer patients

Journal of Hematology and Oncology

Volumn 3, Issue , 2010, Pages

  Robert, Francisco ^a  

^a University of Alabama at Birmingham   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DALTEPARIN; DANAPAROID; DEXAMETHASONE; EMBOLEX; ENOXAPARIN; FONDAPARINUX; HEPARIN; LENALIDOMIDE; LOW MOLECULAR WEIGHT HEPARIN; NADROPARIN; PLACEBO; THALIDOMIDE; TINZAPARIN; WARFARIN; ANTICOAGULANT AGENT;

ANTINEOPLASTIC ACTIVITY; CANCER PATIENT; CANCER SURVIVAL; COMPARATIVE STUDY; COMPRESSION GARMENT; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; HUMAN; NEOPLASM; OUTPATIENT; PATHOPHYSIOLOGY; REVIEW; THROMBOSIS PREVENTION; TREATMENT DURATION; VENOUS THROMBOEMBOLISM; CHEMISTRY; COST BENEFIT ANALYSIS; ECONOMICS; EVALUATION; MOLECULAR WEIGHT; MORTALITY; PREVENTIVE MEDICINE; RISK ASSESSMENT; SURVIVAL;

ANTICOAGULANTS; COST-BENEFIT ANALYSIS; HEPARIN; HUMANS; MOLECULAR WEIGHT; NEOPLASMS; PREVENTIVE MEDICINE; RISK ASSESSMENT; SURVIVAL ANALYSIS; VENOUS THROMBOEMBOLISM;

EID: 77649280047     PISSN: None     EISSN: 17568722     Source Type: Journal    
DOI: 10.1186/1756-8722-3-3     Document Type: Review

References (113)

1. Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. WH Geerts D Bergqvist GF Pineo JA Heit CM Samama MR Lassen CW Colwell American College of Chest Physicians, Chest 8 2008 133 6 Suppl 381S 453S 10.1378/chest.08-0656 18574271
2. Postoperative venous thromboembolism rates vary significantly after different types of major abdominal operations. D Mukherjee AO Lidor KM Chu SL Gearhart ER Haut DC Chang, J Gastrointest Surg 2008 12 2015 2022 10.1007/s11605-008-0600-1 18668299
3. Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy. Risk analysis using Medicare claims data. N Levitan A Dowlati SC Remick HI Tahsildar LD Sivinski R Beyth AA Rimm, Medicine (Baltimore) 1999 78 285 291 10.1097/00005792-199909000-00001 10499070
4. A clinical outcome-based prospective study on venous thromboembolism after cancer surgery: the @RISTOS project. G Agnelli G Bolis L Capussotti RM Scarpa F Tonelli E Bonizzoni M Moia F Parazzini R Rossi F Sonaglia B Valarani C Bianchini G Gussoni, Ann Surg 2006 243 89 95 10.1097/01.sla.0000193959.44677.48 16371741
5. Deep-vein thrombosis and the incidence of subsequent symptomatic cancer. P Prandoni AW Lensing HR Büller A Cogo MH Prins AM Cattelan S Cuppini F Noventa JW ten Cate, N Engl J Med 1992 327 1128 1133 1528208
6. Thrombosis as a harbinger of cancer. P Prandoni A Piccioli, Curr Opin Hematol 2006 13 362 365 10.1097/01.moh.0000239709.47921.04 16888442
7. Systematic review: the Trousseau syndrome revisited: should we screen extensively for cancer in patients with venous thromboembolism? M Carrier G Le Gal PS Wells D Fergusson T Ramsay MA Rodger, Ann Intern Med 2008 149 323 333 18765702
8. Thrombosis and cancer: a short history of Trousseau's syndrome. MH Prins HM Otten, Thrombosis and Cancer London, New York: Informa Healthcare, Lugassy G, Falanga A, Kakkar AK, Rickles FR, 2004 1 10
9. Incidence of venous thromboembolism and its effect on survival among patients with common cancers. HK Chew T Wun D Harvey H Zhou RH White, Arch Intern Med 2006 166 458 464 10.1001/.458 16505267
10. Annual report to the nation on the status of cancer, 1973-1999, featuring implications of age and aging on U.S. cancer burden. BK Edwards HL Howe LA Ries MJ Thun HM Rosenberg R Yancik PA Wingo A Jemal EG Feigal, Cancer 2002 94 2766 2792 10.1002/cncr.10593 12173348
11. Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study. JA Heit MD Silverstein DN Mohr TM Petterson WM O'Fallon LJ Melton, Arch Intern Med 2000 160 809 815 10.1001/archinte.160.6. 809 10737280
12. Prevention of post-operative deep leg vein thrombosis in patients with cancer. AS Gallus, Thromb Haemost 1997 78 126 132 9198141
13. Antithrombotic therapy in cancer. AK Kakkar RC Williamson, BMJ 1999 318 1571 1572 10364099
14. Chemotherapy-induced thrombosis. TC Haddad EW Greeno, Thromb Res 2006 118 555 568 10.1016/j.thromres.2005.10.015 16388837
15. Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis. SR Nalluri D Chu R Keresztes X Zhu S Wu, JAMA 2008 300 2277 2285 10.1001/jama.2008.656 19017914
16. Venous thromboembolism and cancer: guidelines of the Italian Association of Medical Oncology (AIOM). M Mandal A Falanga A Piccioli P Prandoni EM Pogliani R Labianca S Barni working group AIOM, Crit Rev Oncol Hematol 2006 59 194 204 10.1016/j.critrevonc.2006.05.001 16837209
17. American Society of Clinical Oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. GH Lyman AA Khorana A Falanga D Clarke-Pearson C Flowers M Jahanzeb A Kakkar NM Kuderer MN Levine H Liebman D Mendelson G Raskob MR Somerfield P Thodiyil D Trent CW Francis American Society of Clinical Oncology, J Clin Oncol 2007 25 5490 5505 10.1200/JCO.2007.14.1283 17968019
18. Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. C Kearon SR Kahn G Agnelli S Goldhaber GE Raskob AJ Comerota American College of Chest Physicians, Chest 8 2008 133 6 Suppl 454S 545S 10.1378/chest.08-0658 18574272
19. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology. Venous Thromboembolic Disease, V2.2008 http://www.nccn.org/ professionals/physician-gls/PDF/vte.pdf
20. A Trousseau, Clinique Medicale l'Hotel-Dieu de Paris London: New Sydenham Society. Phlegmasia alba dolens 1865 3 654 712
21. From Trousseau to angiogenesis: the link between the haemostatic system and cancer. MR Nijziel R van Oerle HF Hillen K Hamulyk, Neth J Med 2006 64 403 410 17179570
22. The hypercoagulable state of malignancy: pathogenesis and current debate. GJ Caine PS Stonelake GY Lip ST Kehoe, Neoplasia 2002 4 465 473 10.1038/sj.neo.7900263 12407439
23. Markers of coagulation and angiogenesis in cancer-associated venous thromboembolism. N Goldenberg SR Kahn S Solymoss, J Clin Oncol 2003 21 4194 4199 10.1200/JCO.2003.05.165 14615447
24. von Willebrand factor interacts with malignant hematopoietic cell lines: evidence for the presence of specific binding sites and modification of von Willebrand factor structure and function. CM Floyd K Irani PD Kind CM Kessler, J Lab Clin Med 1992 119 467 476 1583402
25. Molecular basis for the relationship between thrombosis and cancer. FR Rickles A Falanga, Thromb Res 2001 102 &22215 V224 10.1016/S0049-3848(01) 00285-7 11516455
26. Thromboprophylaxis rates in US medical centers: success or failure? A Amin S Stemkowski J Lin G Yang, J Thromb Haemost 2007 5 1610 1616 10.1111/j.1538-7836.2007.02650.x 17663733
27. Venous thromboembolism in patients with active cancer. A Seddighzadeh R Shetty SZ Goldhaber, Thromb Haemost 2007 98 656 661 17849056
28. Venous thromboembolism risk and prophylaxis in the acute hospital care setting (ENDORSE study): a multinational cross-sectional study. AT Cohen VF Tapson JF Bergmann SZ Goldhaber AK Kakkar B Deslandes W Huang M Zayaruzny L Emery FA Anderson Jr ENDORSE Investigators, Lancet 2008 371 387 394 10.1016/S0140-6736(08)60202-0 18242412
29. Venous thromboembolism risk and prophylaxis practices in surgical patients with active cancer: findings from the Global ENDORSE Survey [abstract]. AK Kakkar AT Cohen VF Tapson JF Bergmann SZ Goldhaber FA Anderson, Blood 2008 112 984
30. Fatal pulmonary embolism and fatal bleeding in cancer patients with venous thromboembolism: findings from the RIETE registry. M Monreal C Falg M Valdés C Surez F Gabriel C Tolosa J Montes Riete Investigators, J Thromb Haemost 2006 4 1950 1956 10.1111/j.1538-7836.2006.02082.x 16961602
31. Clinical characteristics and management of cancer-associated acute venous thromboembolism: findings from the MASTER Registry. D Imberti G Agnelli W Ageno M Moia G Palareti R Pistelli R Rossi M Verso MASTER Investigators, Haematologica 2008 93 273 278 10.3324/haematol.11458 18223291
32. A meta-analysis and systematic review of the efficacy and safety of anticoagulants as cancer treatment: impact on survival and bleeding complications. NM Kuderer AA Khorana GH Lyman CW Francis, Cancer 2007 110 1149 1161 10.1002/cncr.22892 17634948
33. Prevention of venous thromboembolism in general surgical patients. Results of meta-analysis. GP Clagett JS Reisch, Ann Surg 1998 208 227 240
34. Meta-analysis of low-molecular-weight heparin in the prevention of venous thromboembolism in general surgery. P Mismetti S Laporte JY Darmon A Buchmüller H Decousus, Br J Surg 2001 88 913 930 10.1046/j.0007-1323.2001. 01800.x 11442521
35. Low-molecular-weight heparin and unfractionated heparin in thrombosis prophylaxis: meta-analysis based on original patient data. A Koch S Ziegler H Breitschwerdt N Victor, Thromb Res 2001 102 295 309 10.1016/S0049-3848(01)00251- 1 11369423
36. Low-molecular-weight heparin for the prevention of venous thromboembolism after abdominal surgery. D Bergqvist, Br J Surg 2004 91 965 974 10.1002/bjs.4639 15286956
37. A meta-analysis of thromboembolic prophylaxis following elective total hip arthroplasty. KB Freedman KR Brookenthal RH Fitzgerald Jr S Williams JH Lonner, J Bone Joint Surg Am 2000 82-A 929 938 10901307
38. A systematic review of deep venous thrombosis prophylaxis in cancer patients: implications for improving quality. MJ Leonardi ML McGory CY Ko, Ann Surg Oncol 2007 14 929 936 10.1245/s10434-006-9183-9 17103259
39. Orgaran (Org 10172) or heparin for preventing venous thrombosis after elective surgery for malignant disease? A double-blind, randomized, multicentre comparison. A Gallus J Cade P Ockelford S Hepburn M Maas H Magnani T Bucknall J Stevens F Porteous, Thromb Haemost 1993 70 562 567 7509509
40. Efficacy and safety of enoxaparin versus unfractionated heparin for prevention of deep vein thrombosis in elective cancer surgery: a double-blind randomized multicentre trial with venographic assessment. ENOXACAN Study Group, Br J Surg 1997 84 1099 1103 10.1002/bjs.1800840817 9278651
41. [Prevention of postoperative venous thrombosis. A randomized trial comparing low-dose heparin and low-molecular-weight heparin in gynaecological oncology]. L Heilmann G-F Von Tempelhoff B Herrle B Hojnacki D Schneider HC Michaelis G Wolf, Geburtsh Frauenheilk 1997 57 1 6 10.1055/s-2007-1023030
42. Comparison of enoxaparin and standard heparin in gynaecologic oncologic surgery: a randomized prospective double-blind clinical study. C Baykal A Al E Demirta A Ayhan, Eur J Gynaecol Oncol 2001 22 127 130 11446476
43. Subcutaneous heparin versus low-molecular-weight heparin as thromboprophylaxis in patients undergoing colorectal surgery: results of the canadian colorectal DVT prophylaxis trial: a randomized, double-blind trial. RS McLeod WH Geerts KW Sniderman C Greenwood RC Gregoire BM Taylor RE Silverman KG Atkinson M Burnstein JC Marshall CJ Burul DR Anderson T Ross SR Wilson P Barton Canadian Colorectal Surgery DVT Prophylaxis Trial investigators, Ann Surg 2001 233 438 444 10.1097/00000658-200103000-00020 11224634
44. Randomized clinical trial of postoperative fondaparinux versus perioperative dalteparin for prevention of venous thromboembolism in high-risk abdominal surgery. G Agnelli D Bergqvist AT Cohen AS Gallus M Gent PEGASUS investigators, Br J Surg 2005 92 1212 1220 10.1002/bjs.5154 16175516
45. A randomized study comparing the efficacy and safety of nadroparin 2850 IU (0.3 mL) vs. enoxaparin 4000 IU (40 mg) in the prevention of venous thromboembolism after colorectal surgery for cancer. G Simonneau S Laporte P Mismetti A Derlon K Samii CM Samama JF Bergman FX140 Study Investigators, J Thromb Haemost 2006 4 1693 1700 10.1111/j.1538-7836.2006.02083.x 16796710
46. Low-molecular-weight heparin vs unfractionated heparin for perioperative thromboprophylaxis in patients with cancer: a systematic review and meta-analysis. EA Akl I Terrenato M Barba F Sperati EV Sempos P Muti DJ Cook HJ Schünemann, Arch Intern Med 2008 168 1261 1269 10.1001/archinte.168.12.1261 18574082
47. Prolonged enoxaparin therapy to prevent venous thromboembolism after primary hip or knee replacement. PC Comp TE Spiro RJ Friedman TL Whitsett GJ Johnson GA Gardiner Jr GC Landon M Jové Enoxaparin Clinical Trial Group, J Bone Joint Surg Am 2001 83-A 336 345 11263636
48. Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer. D Bergqvist G Agnelli AT Cohen A Eldor PE Nilsson A Le Moigne-Amrani F Dietrich-Neto ENOXACAN II Investigators, N Engl J Med 2002 346 975 980 10.1056/NEJMoa012385 11919306
49. Prolonged prophylaxis with dalteparin to prevent late thromboembolic complications in patients undergoing major abdominal surgery: a multicenter randomized open-label study. MS Rasmussen LN Jorgensen P Wille-Jørgensen JD Nielsen A Horn AC Mohn L Sømod B Olsen FAME Investigators, J Thromb Haemost 2006 4 2384 2390 10.1111/j.1538-7836.2006.02153.x 16881934
50. Prolonged thromboprophylaxis with low-molecular-weight heparin (dalteparin) following major abdominal surgery for malignancy [abstract]. MS Rasmussen P Wille-Jorgensen LN Jorgensen, Blood 2003 102 186
51. Multicenter evaluation of the use of venous thromboembolism prophylaxis in acutely ill medical patients in Canada. SR Kahn A Panju W Geerts GF Pineo L Desjardins AG Turpie S Glezer L Thabane RJ Sebaldt CURVE study investigators, Thromb Res 2007 119 145 155 10.1016/j.thromres.2006.01.011 16516275
52. Venous thrombosis in cancer patients: insights from the FRONTLINE survey. AK Kakkar M Levine HM Pinedo R Wolff J Wong, Oncologist 2003 8 381 388 10.1634/theoncologist.8-4-381 12897335
53. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients: Prophylaxis in Medical Patients with Enoxaparin Study Group. MM Samama AT Cohen JY Darmon L Desjardins A Eldor C Janbon A Leizorovicz H Nguyen CG Olsson AG Turpie N Weisslinger, N Engl J Med 1999 341 793 800 10.1056/NEJM199909093411103 10477777
54. Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients. A Leizorovicz AT Cohen AG Turpie CG Olsson PT Vaitkus SZ Goldhaber PREVENT Medical Thromboprophylaxis Study Group, Circulation 2004 110 874 879 10.1161/01.CIR.0000138928.83266.24 15289368
55. Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: randomized placebo controlled trial. AT Cohen BL Davidson AS Gallus MR Lassen MH Prins W Tomkowski AG Turpie JF Egberts AW Lensing ARTEMIS Investigators, BMJ 2006 332 325 329 10.1136/bmj.38733.466748.7C 16439370
56. Prevention of venous thromboembolism in medical patients with enoxaparin: a subgroup analysis of the MEDENOX study. R Alikhan AT Cohen S Combe MM Samama L Desjardins A Eldor C Janbon A Leizorovicz CG Olsson AG Turpie, Blood Coagul Fibrinolysis 2003 14 341 346 10.1097/00001721-200306000-00004 12945875
57. European Medicines Agency. http://www.emea.europa.eu/humandocs/PDFs/EPAR/ arixtra/011502en6.pdf
58. Cancer-associated thrombosis: risk factors, candidate biomarkers and a risk model. R Sud AA Khorana, Thromb Res 2009 4 18 21 10.1016/S0049-3848(09) 70137-9
59. Development and validation of a predictive model for chemotherapy- associated thrombosis. AA Khorana NM Kuderer E Culakova GH Lyman CW Francis, Blood 2008 111 4902 7 10.1182/blood-2007-10-116327 18216292
60. Risk stratification for cancer-associated venous thromboembolism. GC Connolly AA Khorana, Best Pract Res Clin Haematol 2009 22 35 47 10.1016/j.beha.2008.12.006 19285271
61. Anticoagulation for the initial treatment of venous thromboembolism in patients with cancer: a systematic review. EA Akl S Rohilla M Barba F Sperati I Terrenato P Muti F Bdair HJ Schünemann, Cancer 2008 113 1685 94 10.1002/cncr.23814 18720360
62. Low-molecular-weight heparin for the long-term treatment of symptomatic venous thromboembolism: meta-analysis of the randomized comparisons with oral anticoagulants. A Iorio F Guercini M Pini, J Thromb Haemost 2003 1 1906 1913 10.1046/j.1538-7836.2003.00364.x 12941030
63. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. AY Lee MN Levine RI Baker C Bowden AK Kakkar M Prins FR Rickles JA Julian S Haley MJ Kovacs M Gent Randomized Comparison of Low-Molecular-Weight Heparin versus Oral Anticoagulant Therapy for the Prevention of Recurrent Venous Thromboembolism in Patients with Cancer (CLOT) Investigators, N Engl J Med 2003 349 146 153 10.1056/NEJMoa025313 12853587
64. Long-term low-molecular-weight heparin versus usual care in proximal-vein thrombosis patients with cancer. RD Hull GF Pineo RF Brant AF Mah N Burke R Dear T Wong R Cook S Solymoss MC Poon G Raskob LITE Trial Investigators, Am J Med 2006 119 1062 1072 10.1016/j.amjmed.2006.02.022 17145251
65. Anticoagulation in patients with cancer: an overview of reviews. EA Akl P Muti HJ Schünemann, Pol Arch Med Wewn 2008 118 183 93 18575417
66. The effectiveness of implementing the weight-based heparin nomogram as a practice guideline. RA Raschke B Gollihare JC Peirce, Arch Intern Med 1996 156 1645 1649 10.1001/archinte.156.15.1645 8694662
67. Continuous intravenous heparin compared with intermittent subcutaneous heparin in the initial treatment of proximal-vein thrombosis. RD Hull GE Raskob J Hirsh RM Jay JR Leclerc WH Geerts D Rosenbloom DL Sackett C Anderson L Harrison, N Engl J Med 1986 315 1109 1114 3531862
68. Parenteral anticoagulants: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. J Hirsh KA Bauer MB Donati M Gould MM Samama JI Weitz American College of Chest Physicians, Chest 8 2008 133 6 Suppl 141S 159S 10.1378/chest.08-0689 18574264
69. Dose adjusted heparin treatment of deep venous thrombosis: a comparison of unfractionated and low-molecular-weight heparin. GF Handeland U Abildgaard HA Holm KE Arnesen, Eur J Clin Pharmacol 1990 39 107 112 10.1007/BF00280041 2174783
70. Low-molecular-weight heparin. J Hirsh MN Levine, Blood 1992 79 1 17 1309422
71. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. J Ansell J Hirsh E Hylek A Jacobson M Crowther G Palareti American College of Chest Physicians, Chest 8 2008 133 6 Suppl 160S 198S 10.1378/chest.08-0670 18574265
72. Effectiveness of warfarin among patients with cancer. AJ Rose JP Sharman A Ozonoff LE Henault EM Hylek, J Gen Intern Med 2007 22 997 1002 10.1007/s11606-007-0228-y 17476542
73. Practical problems and resource implications with the use of warfarin for venous thromboembolism in patients with cancer. PG Morris C Davenport D O'Dwyer C O'Callaghan OS Breathnach L Grogan, Ir J Med Sci 2007 176 165 168 10.1007/s11845-007-0064-4 17638061
74. Warfarin metabolism and drug-drug interactions. RA O'Reilly, The New Dimensions of Warfarin Prophylaxis: Advances in Experimental Medicine and Biology New York, NY: Plenum, Wessler S, Becker CG, Nemerson Y, 1986 198 205 212
75. Patient compliance with outpatient prophylaxis: an observational study. CW Colwell Jr P Pulido ME Hardwick BA Morris, Orthopedics 2005 28 143 147 15751368
76. Preference and compliance in postoperative thromboembolism prophylaxis among gynecologic oncology patients. GL Maxwell I Synan RP Hayes DL Clarke-Pearson, Obstet Gynecol 2002 100 451 455 10.1016/S0029-7844(02)02162-2 12220763
77. The use of long-term low-molecular weight heparin for the treatment of venous thromboembolism in palliative care patients with advanced cancer: a case series of sixty two patients. SI Noble K Hood IG Finlay, Palliat Med 2007 21 473 476 10.1177/0269216307080816 17846086
78. Is long-term low-molecular-weight heparin acceptable to palliative care patients in the treatment of cancer related venous thromboembolism? A qualitative study. SI Noble IG Finlay, Palliat Med 2005 19 197 201 10.1191/0269216305pm1008oa 15920933
79. Dalteparin versus warfarin for the prevention of recurrent venous thromboembolic events in cancer patients: a pharmacoeconomic analysis. G Dranitsaris M Vincent M Crowther, Pharmacoeconomics 2006 24 593 607 10.2165/00019053-200624060-00006 16761906
80. Management of acute proximal deep vein thrombosis: pharmacoeconomic evaluation of outpatient treatment with enoxaparin vs inpatient treatment with unfractionated heparin. AC Spyropoulos JS Hurley GN Ciesla G de Lissovoy, Chest 2002 122 108 114 10.1378/chest.122.1.108 12114345
81. Direct medical costs of venous thromboembolism and subsequent hospital readmission rates: an administrative claims analysis from 30 managed care organizations. AC Spyropoulos J Lin, J Manag Care Pharm 2007 13 475 486 17672809
82. Economic burden of deep-vein thrombosis, pulmonary embolism, and post-thrombotic syndrome. DA MacDougall AL Feliu SJ Boccuzzi J Lin, Am J Health Syst Pharm 2006 63 5 15 10.2146/ajhp060388 17032933
83. Cost for inpatient care of venous thrombosis: a trial of enoxaparin vs standard heparin. G de Lissovoy RD Yusen TE Spiro WC Krupski AH Champion SV Sorensen, Arch Intern Med 2000 160 3160 3165 10.1001/archinte.160.20.3160 11074747
84. Cost-effectiveness of low-molecular-weight heparin in the treatment of proximal deep vein thrombosis. CA Estrada CJ Mansfield GR Heudebert, J Gen Intern Med 2001 15 108 115 10.1046/j.1525-1497.2000.03349.x
85. Low-molecular-weight heparin versus unfractionated heparin in the colonoscopy peri-procedure period: a cost modeling study. JL Goldstein LR Larson BD Yamashita JM Fain GT Schumock, Am J Gastroenterol 2001 6 2360 2366 10.1111/j.1572-0241.2001.04046.x
86. Cost analysis of "bridging therapy" with low-molecular-weight heparin versus unfractionated heparin during temporary interruption of chronic anticoagulation. SL Amorosi K Tsilimingras D Thompson J Fanikos MC Weinstein SZ Goldhaber, Am J Cardiol 2004 93 509 511 10.1016/j.amjcard.2003.10.060 14969639
87. Costs and clinical outcomes associated with low-molecular-weight heparin vs unfractionated heparin for perioperative bridging in patients receiving long-term oral anticoagulant therapy. AC Spyropoulos FJ Frost JS Hurley M Roberts, Chest 2004 125 1642 1650 10.1378/chest.125.5.1642 15136371
88. Cost/death averted with venous thromboembolism prophylaxis in patients undergoing total knee replacement or knee arthroplasty. J Nerurkar WE Wade BC Martin, Pharmacotherapy 2002 22 990 1000 10.1592/phco.22.12.990.33609 12173802
89. Out of hospital antithrombotic prophylaxis after total hip replacement: low-molecular-weight heparin, warfarin, aspirin or nothing? A cost-effectiveness analysis. FP Sarasin H Bounameaux, Thromb Haemost 2002 87 586 592 12008939
90. How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. A Laupacis D Feeny AS Detsky PX Tugwell, CMAJ 1992 146 473 481 1306034
91. The effect of low-molecular-weight heparin on survival in patients with advanced malignancy. CP Klerk SM Smorenburg HM Otten AW Lensing MH Prins F Piovella P Prandoni MM Bos DJ Richel G van Tienhoven HR Büller, J Clin Oncol 2005 23 2130 2135 10.1200/JCO.2005.03.134 15699479
92. Low-molecular-weight heparin, therapy with dalteparin, and survival in advanced cancer: the fragmin advanced malignancy outcome study (FAMOUS). AK Kakkar MN Levine Z Kadziola NR Lemoine V Low HK Patel G Rustin M Thomas M Quigley RC Williamson, J Clin Oncol 2004 22 1944 1948 10.1200/JCO.2004.10.002 15143088
93. Randomized comparison of low-molecular-weight heparin and coumarin derivatives on the survival of patients with cancer and venous thromboembolism. AY Lee FR Rickles JA Julian M Gent RI Baker C Bowden AK Kakkar M Prins MN Levine, J Clin Oncol 2005 23 2123 2129 10.1200/JCO.2005.03.133 15699480
94. Effect of warfarin on survival in small cell carcinoma of the lung. Veterans Administration Study No. 75. LR Zacharski WG Henderson FR Rickles WB Forman CJ Cornell Jr RJ Forcier R Edwards E Headley SH Kim JR O'Donnell R O'Dell K Tornyos HC Kwaan, JAMA 1981 245 831 835 10.1001/jama.245.8.831 6257941
95. Incidence of cancer after prophylaxis with warfarin against recurrent venous thromboembolism. Duration of Anticoagulation Trial. S Schulman P Lindmarker, N Engl J Med 2000 342 1953 1958 10.1056/NEJM200006293422604 10874063
96. Use of warfarin and risk of urogenital cancer: a population-based, nested case-control study. V Tagalakis H Tamim M Blostein JP Collet JA Hanley SR Kahn, Lancet Oncol 2007 8 395 402 10.1016/S1470-2045(07)70046-3 17466896
97. Parenteral anticoagulation for prolonging survival in patients with cancer who have no other indication for anticoagulation. EA Akl FF van Doormaal M Barba G Kamath SY Kim S Kuipers S Middeldorp V Yosuico HO Dickinson HJ Schünemann, Cochrane Database Syst Rev 2007 18 D006652
98. Role of current and emerging antithrombotics in thrombosis and cancer. SA Mousa, Timely Top Med Cardiovasc Dis 2006 10 19 17066136
99. Differential metastasis inhibition by clinically relevant levels of heparins - correlation with selectin inhibition, not antithrombotic activity. JL Stevenson SH Choi A Varki, Clin Cancer Res 2005 11 7003 7011 10.1158/1078-0432.CCR-05-1131 16203794
100. Modulatory effects of heparin and short-length oligosaccharides of heparin on the metastasis and growth of LMD MDA-MB 231 breast cancer cells in vivo. P Mellor JR Harvey KJ Murphy D Pye G O'Boyle TW Lennard JA Kirby S Ali, Br J Cancer 2007 97 761 768 10.1038/sj.bjc.6603928 17726466
101. Angiogenesis inhibition and tumor regression caused by heparin or a heparin fragment in the presence of cortisone. J Folkman R Langer RJ Linhardt C Haudenschild S Taylor, Science 1983 221 719 725 10.1126/science.6192498 6192498
102. Inhibition of endothelial cell tube formation by the low-molecular-weight heparin, tinzaparin, is mediated by tissue factor pathway inhibitor. SA Mousa S Mohamed, Thromb Haemost 2004 92 627 633 15351861
103. The complex effects of heparins on cancer progression and metastasis in experimental studies. SM Smorenburg CJ Van Noorden, Pharmacol Rev 2001 53 93 105 11171940
104. Differentiation of low-molecular-weight heparins: impact on the future of the management of thrombosis. J Fareed Q Ma M Florian J Maddineni O Iqbal DA Hoppensteadt RL Bick, Semin Thromb Hemost 2004 30 89 104 10.1055/s-2004-861513 15085470
105. Differentiating low-molecular-weight heparins based on chemical, biological, and pharmacologic properties: implications for the development of generic versions of low-molecular-weight heparins. WP Jeske JM Walenga DA Hoppensteadt C Vandenberg A Brubaker C Adiguzel M Bakhos J Fareed, Semin Thromb Hemost 2008 34 74 85 10.1055/s-2008-1066026 18393144
106. Non-anticoagulant heparins and inhibition of cancer. B Casu I Vlodavsky RD Sanderson, Pathophysiol Haemost Thromb 2008 36 195 203 10.1159/000175157 19176992
107. Changing trends in anti-coagulant therapies. Are heparins and oral anti-coagulants challenged? J Fareed O Iqbal J Cunanan M Demir R Wahi M Clarke C Adiguzel R Bick, Int Angiol 2008 27 176 192 18506123
108. New antithrombotic drugs: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. JI Weitz J Hirsh MM Samama American College of Chest Physicians, Chest 8 2008 133 234S 256S 10.1378/chest.08-0673 18574267
109. New antithrombotic drugs: potential for use in oncology. MN Levine, J Clin Oncol 2009 27 4912 8 10.1200/JCO.2009.24.7346 19738103
110. AVE5026: A new hemisynthetic ultra low molecular weight heparin (ULMWH) with enriched anti-Xa activity and enhanced antithrombotic activity for management of cancer associated thrombosis. D Hoppensteadt W Jeske JM Walenga J Fareed, J Clin Oncol 2008 26 bstr 14653
111. Dabigatran Etexilate: Pivotal Trials for Venous Thromboembolism Prophylaxis After Hip or Knee Arthroplasty. BI Eriksson R Friedman, Clin Appl Thromb Hemost 2009 19648146
112. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. BI Eriksson LC Borris RJ Friedman S Haas MV Huisman AK Kakkar TJ Bandel H Beckmann E Muehlhofer F Misselwitz W Geerts RECORD1 Study Group, N Engl J Med 2008 358 2765 75 10.1056/NEJMoa0800374 18579811
113. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial. AG Turpie MR Lassen BL Davidson KA Bauer M Gent LM Kwong FD Cushner PA Lotke SD Berkowitz TJ Bandel A Benson F Misselwitz WD Fisher RECORD4 Investigators, Lancet 2009 373 1673 80 10.1016/S0140-6736(09)60734-0 19411100